title: Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy.
abstract: Helicobacter pylori is a gram-negative bacterium that colonizes the human gastric mucosa causing gastritis and peptic ulcer and increasing the risk of gastric cancer. The efficacy of current antibiotic-based therapies can be limited by problems of patient compliance and increasing antibiotic resistance; the vaccine approach can overcome these limits. The present study describes the therapeutic vaccination of experimentally H. pylori-infected beagle dogs, an animal model that reproduces several aspects of the human infection with H. pylori. The vaccine consisted of three recombinant H. pylori antigens, CagA, VacA, and NAP, formulated at different doses (10, 25, or 50 microg each) with alum and administered intramuscularly either weekly or monthly. No adverse effects were observed after vaccination and a good immunoglobulin G response was generated against each of the three antigens. Bacterial colonization and gastritis were decreased after the completion of the vaccination cycle, especially in the case of the monthly immunization schedule. In conclusion, therapeutic vaccination in the beagle dog model was safe and immunogenic and was able to limit H. pylori colonization and the related gastric pathology.
authors.affiliation: Department of Veterinary Science, University of Camerino, Italy.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Rossi
authors.forename: Paolo
authors.initials: P
authors.lastname: Ruggiero
authors.forename: Samuele
authors.initials: S
authors.lastname: Peppoloni
authors.forename: Laura
authors.initials: L
authors.lastname: Pancotto
authors.forename: Damiano
authors.initials: D
authors.lastname: Fortuna
authors.forename: Laura
authors.initials: L
authors.lastname: Lauretti
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Volpini
authors.forename: Silvia
authors.initials: S
authors.lastname: Mancianti
authors.forename: Michele
authors.initials: M
authors.lastname: Corazza
authors.forename: Ennio
authors.initials: E
authors.lastname: Taccini
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Pisa
authors.forename: Rino
authors.initials: R
authors.lastname: Rappuoli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Del Giudice
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology*; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D004195:Disease Models, Animal; D004285:Dogs; D005756:Gastritis / Q000517:prevention & control; D016481:Helicobacter Infections / Q000517:prevention & control*; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D011994:Recombinant Proteins / Q000276:immunology*; D016896:Treatment Outcome; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D011994:Recombinant Proteins; C074689:VacA protein, Helicobacter pylori; C080866:cagA protein, Helicobacter pylori; C092412:neutrophil-activating protein A, Helicobacter pylori